Literature DB >> 30307404

Role of protein kinase C, PI3 kinase, tyrosine kinases, NO-synthase, KATP channels and MPT pore in the signaling pathway of the cardioprotective effect of chronic continuous hypoxia.

Sergey Y Tsibulnikov1, Leonid N Maslov, Natalia V Naryzhnaya, Huijie Ma, Yury B Lishmanov, Peter R Oeltgen, Keith Garlid.   

Abstract

It was established that adaptation to chronic continuous normobaric hypoxia (CCNH) increases cardiac tolerance to ischemia and reperfusion. It was performed coronary artery occlusion (20 min) and reperfusion (3 h) in Wistar rats. CCNH promoted a decrease in the infarct size/area at risk ratio in 2-fold. CCNH promoted an increase in the nitrite/nitrate levels in blood serum and myocardium. Pretreatment with protein kinase C (PKC) inhibitor chelerythrine, NO-synthase (NOS) inhibitor L-NAME, iNOS inhibitor S-methylisothiourea, KATP channel blocker glibenclamide, mitoKATP channel blocker 5-hydroxydecanoic acid abolished the infarct-reducing effect of CCNH. The non-selective tyrosine kinase inhibitor genistein attenuated but not eliminated infarct-sparing effect of CCNH. The nNOS inhibitor 7-nitroindazole, sarcKATP channel blocker HMR 1098, MPT pore inhibitor atractyloside, PI3 kinase inhibitor wortmannin did not reverse infarct-limiting effect of CCNH. It was concluded that infarct-reducing effect of CCNH is mediated via PKC, iNOS activation and mitoKATP channel opening. While nNOS, PI3 kinase, sarcKATP channel, MPT pore are not involved in the development of CCNH-induced cardiac tolerance to impact of ischemia-reperfusion.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30307404     DOI: 10.4149/gpb_2018013

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  1 in total

Review 1.  The involvement of protein kinases in the cardioprotective effect of chronic hypoxia.

Authors:  N V Naryzhnaya; H-J Ma; L N Maslov
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.